Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

3.7%

1 terminated/withdrawn out of 27 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

33%

9 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
8(33.3%)
Phase 3
7(29.2%)
N/A
6(25.0%)
Phase 4
2(8.3%)
Phase 1
1(4.2%)
24Total
Phase 2(8)
Phase 3(7)
N/A(6)
Phase 4(2)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (27)

Showing 20 of 27 trials
NCT04320979Phase 3Active Not Recruiting

Postmastecomy Internal Mammary Nodal Irradiation for High-risk Breast Cancer Patients

Role: collaborator

NCT05955391Phase 2Active Not Recruiting

TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)

Role: collaborator

NCT06863831Not ApplicableEnrolling By Invitation

A Multicenter Trial of YSQTG vs. Simulated Agents With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy for EC

Role: collaborator

NCT06105203Not ApplicableNot Yet Recruiting

RATME Vs LATME in Middle and Low Rectal Cancer

Role: collaborator

NCT04217967Phase 4Completed

Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients

Role: collaborator

NCT06426056Phase 2Not Yet Recruiting

Nab-Paclitaxel Plus Cisplatin With Concurrent Radiotherapy for Patients With Locally Advanced Cervical Cancer: A Multicentre, Single-arm, Phase II Trial.

Role: collaborator

NCT04543695Phase 2Active Not Recruiting

A Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer

Role: collaborator

NCT03591445Not ApplicableCompleted

Is Bronchoscopy Necessary in the Preoperative Workup of GGO Lung Cancer?(ECTOP-1005)

Role: collaborator

NCT03214003Not ApplicableCompleted

Twice-daily SIB Radiotherapy Versus Standard Radiotherapy for Patients With SCLC

Role: collaborator

NCT03236649Phase 3Terminated

The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects

Role: collaborator

NCT04922567Phase 2Recruiting

Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

Role: collaborator

NCT05429918Unknown

Ibrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged ≤65 Years

Role: collaborator

NCT05406154Unknown

Ibrutinib Combined With Bendamustine and Rituximab in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged > 65 Years

Role: collaborator

NCT03955367Phase 3Unknown

Pelvic RT Versus Prophylactic Extended-field RT in Patients With Cervical Cancer

Role: collaborator

NCT05105464Phase 1Unknown

A Study to Investigate the Safety of SYHA1815 in Subjects With Unresectable Locally Advanced or Metastatic Solid Tumors

Role: collaborator

NCT04819685Phase 4Unknown

Application of KANG FU PEN in Radical Concurrent Radiotherapy and Chemotherapy for Cervical Cancer to Prevent and Treat Radiation-induced Rectal Injury

Role: collaborator

NCT04666805Unknown

Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast

Role: collaborator

NCT01405079Phase 3Unknown

Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation

Role: collaborator

NCT02958111Phase 3Unknown

Single-agent Capecitabine as Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Role: collaborator

NCT01407822Phase 2Unknown

Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer

Role: collaborator